Segment Data (Tables)

12 Months Ended

Sep. 30, 2021

Revenue from External Customers by Geographic Areas

Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.


(Millions of dollars)	2021						2020						2019
	United States		International		Total		United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	2,246	$	1,812	$	4,057	$	1,972	$	1,583	$	3,555	$	2,037	$	1,811	$	3,848
Medication Management Solutions	1,863		570		2,432		1,865		589		2,454		2,115		525		2,640
Diabetes Care	606		554		1,160		562		522		1,084		573		538		1,110
Pharmaceutical Systems	428		1,401		1,829		404		1,184		1,588		392		1,073		1,465
Total segment revenues	$	5,142	$	4,336	$	9,479	$	4,802	$	3,878	$	8,680	$	5,116	$	3,947	$	9,064

Life Sciences
Integrated Diagnostic Solutions	$	2,477	$	2,748	$	5,225	$	1,872	$	1,659	$	3,532	$	1,446	$	1,659	$	3,106
Biosciences	503		802		1,305		465		678		1,143		485		709		1,194
Total segment revenues	$	2,980	$	3,550	$	6,530	$	2,337	$	2,337	$	4,675	$	1,931	$	2,368	$	4,300

Interventional
Surgery	$	1,023	$	274	$	1,296	$	891	$	230	$	1,121	$	977	$	264	$	1,242
Peripheral Intervention	931		780		1,711		871		640		1,511		917		657		1,574
Urology and Critical Care	894		338		1,232		815		315		1,130		787		323		1,110
Total segment revenues	$	2,847	$	1,392	$	4,239	$	2,577	$	1,186	$	3,762	$	2,682	$	1,244	$	3,926

Total Company revenues	$	10,969	$	9,279	$	20,248	$	9,716	$	7,401	$	17,117	$	9,730	$	7,560	$	17,290

Financial Information for Company's Segments


(Millions of dollars)	2021		2020		2019
Income Before Income Taxes
Medical (a) (b) (c)	$	2,583	$	2,274	$	2,824
Life Sciences (d)	2,391		1,405		1,248
Interventional (e)	933		724		903
Total Segment Operating Income	5,907		4,403		4,976
Acquisitions and other restructurings	(185)		(309)		(480)
Unallocated other operating expense, net (f)	(238)		(363)		(579)
Net interest expense	(460)		(521)		(627)
Other unallocated items (g)	(2,783)		(2,224)		(2,115)
Total Income Before Income Taxes	$	2,242	$	985	$	1,176
Capital Expenditures
Medical	$	777	$	477	$	577
Life Sciences	297		192		230
Interventional	125		119		120
Corporate and All Other	32		22		30
Total Capital Expenditures	$	1,231	$	810	$	957
Depreciation and Amortization
Medical	$	1,140	$	1,104	$	1,073
Life Sciences	352		286		284
Interventional	769		750		881
Corporate and All Other	12		14		14
Total Depreciation and Amortization	$	2,273	$	2,154	$	2,253

(a)The amounts in 2021 and 2020 include charges of $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD AlarisTM infusion pumps in the Medication Management Solutions unit.

(b)The amount in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units.

(c)The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.

(d)The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units.

(e)The amount in 2019 included a charge of $30 million recorded to Research and development expense to write down the carrying value of certain intangible assets in the Surgery unit.

(f)The amounts in 2021, 2020 and 2019 include pre-tax charges of $361 million, $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The amount in 2021 also includes gains of $158 million on sale-leaseback transactions, which are further discussed in Note 17, and $35 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 10.

(g)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment

Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.


(Millions of dollars)	2021		2020		2019
Revenues
United States	$	10,969	$	9,716	$	9,730
EMEA (a)	4,751		3,928		3,837
Greater Asia	3,272		2,568		2,726
Other (a)	1,255		905		997
	$	20,248	$	17,117	$	17,290
Long-Lived Assets
United States	$	36,037	$	36,468	$	37,053
EMEA (a)	6,004		5,890		5,519
Greater Asia	1,662		1,521		1,328
Other (a)	860		753		824
Corporate	465		411		377
	$	45,029	$	45,043	$	45,101

(a)The amounts in fiscal years 2020 and 2019 reflect the reclassifications of $448 million and $478 million, respectively, of revenues and $55 million and $37 million, respectively, of long-lived assets in the Middle East and Africa.